

Analytical Study of Some Anti-Viral Drugs

Presented for Partial Fulfillment of Master Degree
in Pharmaceutical Sciences
(Pharmaceutical Analytical Chemistry)

By

Marwa Abd El-Rahman Mohammed

B.Sc.Pharmacy, Ain Shams University, 2003

Under Supervision of

Assistant Prof. Dr.

**Maha Farouk Abd El-
Ghany**

Assistant Professor of
Pharmaceutical

Analytical Chemistry

Faculty of Pharmacy –Ain
Shams University

Assistant Prof. Dr.

**Lobna Abd El-Aziz
Hussein**

Assistant Professor of
Pharmaceutical

Analytical Chemistry

Faculty of Pharmacy –Ain
Shams University

Dr.

Faten Abd El -Aziz Fatahalla

Chairman of National Organization for
Research and Control of Biologicals

ACKNOWLEDGMENT

No words can ever express my gratitude to ALLAH, **who** guides and aids me in every step in my life.

I would like to express my deepest gratitude to Assistant Prof. Dr. Maha Farouk ,the head of Pharmaceutical Analytical Chemistry Department , Faculty of Pharmacy, Ain Shams University , for her valuable efforts in suggesting the point ,constant advising and supervision.

I am greatly indebted to Dr. Lobna Abd El- Aziz, Assistant Prof. of Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, for her keen supervision, valuable assistance, beneficial discussion, great effort and continuous encouragement.

I am also deeply grateful to Dr. Faten Abd El-Aziz, Chairman of National Organization for Research and Control of Biologicals , for her keen supervision, kind guidance , valuable advices .

I wish to express my cordial thanks and gratefulness to my parents, brother and my sister for their continuous encouragement and support.

Finally, I wish to express my appreciation and thanks to everyone who helped and supported me to accomplish this work.

Marwa Abd El Rahman

List of abbreviations

INN	International Non proprietary Name
USAN	United State Adopted Name
CZE	Capillary Zone Electrophoresis
MEKC	Micellar Electro Kinetic Chromatography
HPLC	High Performance Liquid Chromatography
UHPLC	Ultra High Pressure Liquid Chromatography
RRLC	Rapid Resolution Liquid Chromatography
UPLC	Ultra Performance Liquid Chromatography
RSLC	Rapid Separation Liquid Chromatography
FPLC	Fast Performance Liquid Chromatography
DAD	Diode Array Detector
i.d.	Internal diameter
B. No.	Batch number
M	Molar
SD	Standard deviation
RSD	Relative Standard Deviation
r	Correlation coefficient
LOD	Limit of detection
LOQ	Limit of quantitation
QC	Quality Control
n	Number of observations
IS	Internal Standard
TLC	Thin Layer Chromatography
R _f	Retardation factor
$\Delta\lambda$	Spectral bandwidth
¹ DD	First derivative of the ratio spectra
ICH	International Conference on Harmonization

CONTENTS

PART I: Introduction

Section A

General Introduction

	Page
Virus and Anti-Viral drugs	1
Drug Stability	6

Section B

Literature Review

I.B.1.	Valaciclovir Hydrochloride	9
I.B.1.1.	Methods of analysis	10
I.B.1.1.1.	Spectroscopic methods	10
I.B.1.1.1.1.	Colorimetric methods	10
I.B.1.1.1.2.	UV-spectrophotometric methods	10
I.B.1.1.2.	Electrochemical methods	11
I.B.1.1.3.	Capillary Zone Electrophoresis	11
I.B.1.1.4.	Micellar Electrokinetic Chromatography	11
I.B.1.1.5.	High Performance Liquid chromatography	12
I.B.2.	Oseltamivir Phosphate	15
I.B.2.1.	Methods of analysis	16
I.B.2.1.1.	Electrochemical methods	16
I.B.2.1.2.	Spectroscopic methods	16
I.B.2.1.2.1.	Colorimetric methods	16
I.B.2.1.2.2.	Spectrofluorimetric methods	16
I.B.2.1.3.	Capillary Zone Electrophoresis	17
I.B.2.1.4.	High Performance Liquid chromatography	17
I.B.3.	Zanamivir	21
I.B.3.1.	Methods of analysis	22
I.B.3.1.1.	High Performance Liquid chromatography	22

Part II: Chromatographic methods

Section A

Introduction to Ultra High Pressure Liquid Chromatography

II.A.1.	Fast liquid chromatography(Fast LC) techniques	24
II.A.2.	Ultra High Pressure Liquid Chromatography(UHPLC)	25
II.A.3.	UHPLC instrumentation	28

Section B

Stability Indicating RRLC Method for Determination of Valaciclovir HCl in Presence of Its Acid-and Alkaline- Dregradates.

II.B.1.	Experimental	31
II.B.1.1.	Instrumentation	31
II.B.1.2.	Samples ,chemicals and reagents	31
II.B.1.2.1	Samples	31
II.B.1.2.1.1	Pure standard	31
II.B.1.2.1.2	Market pharmaceutical dosage form	32
II.B.1.2.2	Chemicals and reagents	32
II.B.1.3.	Standard solutions	32
II.B.1.3.1.	Stock standard solution of valaciclovir HCl (0.1mg ml ⁻¹)	32
II.B.1.3.2.	Alkaline-degradate solution (0.1mg ml ⁻¹)	33
II.B.1.3.3.	Acid-degradate solution (0.1mg ml ⁻¹)	33
II.B.1.4.	Procedures	33
II.B.1.4.1.	Chromatographic conditions	33
II.B.1.4.2.	Method validation	34
II.B.1.4.2.1	Linearity	34
II.B.1.4.2.2.	Accuracy	34
II.B.1.4.2.3.	Precision	35
II.B.1.4.2.3.a	Repeatability	35
II.B.1.4.2.3.b	Intermediate precision	35
II.B.1.4.2.4.	Selectivity	35
II.B.1.4.2.5.	Robustness	36
II.B.1.4.2.6.	Application to the pharmaceutical formulations	36
II.B.1.4.2.7.	Validation by standard addition	36
II.B.2.	Results and Discussion	37

Section C

Bioanalytical RRLC Method for Determination of Aciclovir, The Active Metabolite of Valaciclovir, in Spiked Human Plasma

II.C.1.	Introduction	49
II.C.2.	Experimental	49
II.C.2.1.	Instrumentation	49
II.C.2.2.	Samples ,chemicals and reagents	50
II.C.2.2.1	Pure standard	50
II.C.2.2.2	Chemicals and reagents	50
II.C.2.3.	Standard solutions	51
II.C.2.3.1	Stock standard solution of aciclovir (1.0mg ml ⁻¹)	51
II.C.2.3.2.	Working standard solutions of aciclovir	51
II.C.2.3.3.	Ampicillin sodium internal standard solution (25.0 mg ml ⁻¹)	51
II.C.2.4.	Procedures	51
II.C.2.4.1	Chromatographic conditions	51
II.C.2.4.2	Sample preparation	52
II.C.2.4.2.1	Spiked plasma samples preparation	52
II.C.2.4.3.	Method validation	52
II.C.2.4.3.1.	Linearity	52
II.C.2.4.3.2.	Accuracy	53
II.C.2.4.3.3.	Precision	53
II.C.2.4.3.3.a.	Repeatability	53
II.C.2.4.3.3.b.	Intermediate precision	53
II.C.2.4.3.4.	Selectivity	54
II.C.2.4.3.5.	Recovery	54
II.C.2.4.3.6.	Stability	54
II.C.2.4.3.6.a.	Freeze-thaw stability	54
II.C.2.4.3.6.b.	Short -term stability (bench- top stability)	55
II.C.2.4.3.6.c.	Long- term stability	55
II.C.3.	Results and discussion	55

Section D

Stability Indicating RP- RRLC for Determination of Oseltamivir Phosphate in Presence of Its Alkaline- Degradate

II.D.1.	Experimental	67
II.D.1.1.	Instrumentation	67
II.D.1.2.	Samples ,chemicals and reagents	67
II.D.1.2.1.	Samples	67
II.D.1.2.1.1.	Pure standard	67
II.D.1.2.1.2.	Market pharmaceutical dosage form	68

II.D.1.2.2.	Chemicals and reagents	68
II.D.1.3.	Standard solutions	68
II.D.1.3.1	Stock standard solution of oseltamivir phosphate (1.0 mg ml ⁻¹)	68
II.D.1.3.2.	Alkaline-degradate solution (0.1mg ml ⁻¹)	69
II.D.1.4.	Procedures	69
II. D.1.4.1.	Chromatographic conditions	69
II.D.1.4.2.	Method validation	70
II.D.1.4.2.1.	Linearity	70
II.D.1.4.2.2.	Accuracy	70
II.D.1.4.2.3.	Precision	71
II.D.1.4.2.3.a.	Repeatability	71
II.D.1.4.2.3.b.	Intermediate precision	71
II.D.1.4.2.4.	Selectivity	71
II.D.1.4.2.5.	Robustness	72
II.D.1.4.2.6.	Application to the pharmaceutical formulations	72
II.D.1.4.2.7.	Validation by standard addition technique	72
II.D.2.	Results and discussion	73

Section E

Stability Indicating RP-HPLC for Determination of Valaciclovir HCl in Presence of Its Acid – and Alkaline- Degradates

II.E.1	Introduction	83
II.E.2.	Experimental	85
II.E.2.1.	Instrumentation	85
II.E.2.2.	Samples ,chemicals and reagents	85
II.E.2.2.1	Samples	85
II.E.2.2.2.	Chemicals and reagents	85
II.E.2.3.	Standard solutions	86
II.E.2.3.1.	Stock standard solution of valaciclovir HCl (0.25mg ml ⁻¹)	86
II.E.2.3.2.	Alkaline-degradate solution (0.1mg ml ⁻¹)	86
II.E.2.3.3.	Acid-degradate solution (0.1mg ml ⁻¹)	86
II.E.2.4.	Procedures	87
II.E.2.4.1.	Chromatographic conditions	87
II.E.2.4.2.	Method validation	87
II.E.2.4.2.1.	Linearity	87
II.E.2.4.2.2.	Accuracy	88
II.E.2.4.2.3.	Precision	88
II.E.2.4.2.3.a.	Repeatability	88
II.E.2.4.2.3.b.	Intermediate precision	88

II.E.2.4.2.4.	Selectivity	89
II.E.2.4.2.5.	Robustness	89
II.E.2.4.2.6.	Application to the pharmaceutical formulations	89
II.E.2.4.2.7.	Validation by standard addition technique	90
II.E.3.	Results and discussion	90

Section F

Stability Indicating RP-HPLC for Determination of Oseltamivir Phosphate in Presence of Its Alkaline- Degradate

II.F.1.	Experimental	100
II.F.1.1.	Instrumentation	100
II.F.1.2.	Samples ,chemicals and reagents	100
II.F.1.2.1.	Samples	100
II.F.1.2.2.	Chemicals and reagents	100
II.F.1.3.	Standard solutions	101
II.F.1.3.1	Stock standard solution of oseltamivir phosphate (0.1 mg ml ⁻¹)	101
II.F.1.3.2.	Alkaline-degradate solution (0.1mg ml ⁻¹)	101
II.F.1.4.	Procedures	101
II.F.1.4.1.	Chromatographic conditions	101
II.F.1.4.2.	Method validation	102
II.F.1.4.2.1.	Linearity	102
II.F.1.4.2.2.	Accuracy	102
II.F.1.4.2.3.	Precision	103
II.F.1.4.2.3.a.	Repeatability	103
II.F.1.4.2.3.b.	Intermediate precision	103
II.F.1.4.2.4.	Selectivity	103
II.F.1.4.2.5.	Robustness	104
II.F.1.4.2.6.	Application to the pharmaceutical formulations	104
II.F.1.4.2.7.	Validation by standard addition technique	104
II.F.2.	Results and discussion	105

Section G

Stability Indicating RP-HPLC for Determination of Zanamivir in Presence of Its Acid-Degradate

II.G.1.	Experimental	115
II.G.1.1.	Instrumentation	115
II.G.1.2.	Samples ,chemicals and reagents	115
II.G.1.2.1.	Samples	115

II.G.1.2.1.1.	Pure standard	115
II.G.1.2.1.2.	Market pharmaceutical dosage form	115
II.G.1.2.2.	Chemicals and reagents	116
II.G.1.3.	Standard solutions	116
II.G.1.3.1.	Stock standard solution of zanamivir (0.2mg ml^{-1})	116
II.G.1.3.2.	Acid-degrade solution (0.2mg ml^{-1})	116
II.G.1.4.	Procedures	117
II.G.1.4.1.	Chromatographic conditions	117
II.G.1.4.2.	Method validation	117
II.G.1.4.2.1.	Linearity	117
II.G.1.4.2.2.	Accuracy	118
II.G.1.4.2.3.	Precision	118
II.G.1.4.2.3.a.	Repeatability	118
II.G.1.4.2.3.b.	Intermediate precision	118
II.G.1.4.2.4.	Selectivity	119
II.G.1.4.2.5.	Robustness	119
II.G.1.4.2.6.	Application to the pharmaceutical formulations	119
II.G.1.4.2.7.	Validation by standard addition technique	120
II.G.2.	Results and discussion	120

Section H

Stability Indicating TLC Spectrodensitometric Method for Determination of Valaciclovir HCl in Presence of Its Alkaline - Degradate

II.H.1.	Introduction	130
II.H.2.	Experimental	132
II.H.2.1.	Instrumentation	132
II.H.2.2.	Samples ,chemicals and reagents	132
II.H.2.2.1.	Samples	132
II.H.2.2.2.	Chemicals and reagents	132
II.H.2.3.	Standard solutions	133
II.H.2.3.1.	Stock standard solution of valaciclovir Hydrochloride (1.0mg ml^{-1})	133
II.H.2.3.2.	Alkaline-degrade solution (1.0mg ml^{-1})	133
II.H.2.4.	Procedures	134
II.H.2.4.1.	Chromatographic conditions	134
II.H.2.4.2.	Method validation	134
II.H.2.4.2.1.	Linearity	134
II.H.2.4.2.2.	Accuracy	135
II.H.2.4.2.3.	Precision	135
II.H.2.4.2.3.a.	Repeatability	135
II.H.2.4.2.3.b.	Intermediate precision	135

II.H.2.4.2.4.	Selectivity	136
II.H.2.4.2.6	Application to the pharmaceutical formulations	136
II.H.2.4.2.7	Validation by standard addition technique	136
II.H.3.	Results and discussion	137

Section I

Stability indicating TLC Spectrodensitometric Method for determination of Oseltamivir Phosphate in Presence of Its Alkaline - Degradate

II.I.1.	Experimental	146
II.I.1.1.	Instrumentation	146
II.I.1.2.	Samples ,chemicals and reagents	146
II.I.1.2.1.	Samples	146
II.I.1.2.2.	Chemicals and reagents	146
II.I.1.3.	Standard solutions	147
II.I.1.3.1.	Stock standard solution of oseltamivir phosphate (5.0mg ml ⁻¹)	147
II.I.1.3.2.	Alkaline-degradate solution (5.0mg ml ⁻¹)	147
II.I.1.4.	Procedures	148
II.I.1.4.1.	Chromatographic conditions	148
II.I.1.4.2.	Method validation	148
II.I.1.4.2.1	Linearity	148
II.I.1.4.2.2	Accuracy	149
II.I.1.4.2.3.	Precision	149
II.I.1.4.2.3.a.	Repeatability	149
II.I.1.4.2.3.b.	Intermediate precision	149
II.I.1.4.2.4.	Selectivity	150
II.I.1.4.2.5.	Application to the pharmaceutical formulations	150
II.I.1.4.2.6.	Validation by standard addition technique	150
II.I.2.	Results and discussion	151

PARTIII: Spectrophotometric methods

Section A

Stability Indicating First Derivative of Ratio Spectra Spectrophotometric Method for determination of Oseltamivir Phosphate in Presence of its Alkaline- Degradate

III.A.1.	Introduction	159
III.A.2.	Experimental	161
III.A.2.1.	Instrumentation	161
III.A.2.2.	Samples ,chemicals and reagents	161

III.A.2.2.1.	Samples	161
III.A.2.2.2.	Chemicals and reagents	162
III.A.2.3.	Standard solutions	162
III.A.2.3.1.	Stock standard solution of oseltamivir phosphate (0.1mg ml ⁻¹)	162
III.A.2.3.2.	Alkaline-degrade solution (0.1mg ml ⁻¹)	162
III.A.2.4.	Procedures	163
III.A.2.4.1.	Spectral characteristic of oseltamivir phosphate and its alkaline-degrade	163
III.A.2.4.2.	Method validation	163
III.A.2.4.2.1.	Linearity	163
III.A.2.4.2.2.	Accuracy	164
III.A.2.4.2.3.	Precision	164
III.A.2.4.2.3.a.	Repeatability	164
III.A.2.4.2.3.b.	Intermediate precision	165
III.A.2.4.2.4.	Selectivity	165
III.A.2.4.2.5.	Application to the pharmaceutical formulations	165
III.A.2.4.2.6.	Validation by standard addition technique	166
III.A.3.	Results and discussion	166

Section B

Stability Indicating First Derivative of Ratio Spectra Spectrophotometric Method for determination of Zanamivir in Presence of its acidic- Degradate

III.B.1.	Experimental	176
III.B.1.1.	Instrumentation	176
III.B.1.2.	Samples ,chemicals and reagents	176
III.B.1.2.1.	Samples	176
III.B.1.2.2.	Chemicals and reagents	176
III.B.1.3.	Standard solutions	177
III.B.1.3.1.	Stock standard solution of zanamivir (0.1mg ml ⁻¹)	177
III.B.1.3.2.	Acid-degrade solution (0.1mg ml ⁻¹)	177
III.B.1.4.	Procedures	178
III.B.1.4.1.	Spectral characteristic of zanamivir and its acid - degrade	178
III.B.1.4.2.	Method validation	178
III.B.1.4.2.1.	Linearity	178
III.B.1.4.2.2.	Accuracy	179
III.B.1.4.2.3.	Precision	179
III.B.1.4.2.3.a.	Repeatability	179
III.B.1.4.2.3.b.	Intermediate precision	179
III.B.1.4.2.4.	Selectivity	180
III.B.1.4.2.5.	Application to the pharmaceutical formulations	180
III.B.1.4.2.6.	Validation by standard addition technique	180

III.B.2.	Results and discussion	181
	PART IV	
	General Discussion	
IV.	General Discussion	190
	PART V	
	References	
V.	References	196

List of Tables

Table No.		Page No.
1	Results of assay validation obtained using the proposed RRLC for determination of valaciclovir HCl in presence of its acid- and alkaline - degradates.	45
2	Accuracy of the proposed RRLC method for the analysis of pure samples of valaciclovir HCl.	46
3	Determination of valaciclovir HCl in laboratory prepared mixtures containing its acid- and alkaline –degradates by the proposed RRLC method.	46
4	System suitability parameters of the proposed RRLC method for determination of valaciclovir HCl.	47
5	Results from robustness testing of the proposed RRLC method	47
6	Determination of valaciclovir HCl in pharmaceutical formulation by the proposed RRLC method and application of standard addition technique.	48
7	Statistical comparison between the proposed RRLC method and the manufacturer * method for determination of valaciclovir HCl.	48
8	Assay parameters and regression characteristic of determination of aciclovir in human plasma sample by proposed RRLC method .	63
9	Recovery of aciclovir from human plasma.	63
10	Accuracy of the proposed RRLC method for the determination of aciclovir in spiked human plasma.	64
11	Intra- and inter – day precision and accuracy for the determination of aciclovir in human plasma.	64
12	Summary for stability of aciclovir in human plasma at varying conditions.	65
13	Statistical comparison between the proposed RRLC method and the published method for determination of aciclovir in human plasma.	66
14	Results of assay validation obtained using the proposed RRLC method for determination of oseltamivir phosphate in presence of its alkaline – degradate.	79
15	Accuracy of the proposed RRLC method for the analysis of pure samples of oseltamivir phosphate.	80

16	Determination of oseltamivir phosphate in laboratory prepared mixtures containing its alkaline –degradata by the proposed RRLC method.	80
17	System suitability parameters of the proposed RRLC method for determination of oseltamivir phosphate.	81
18	Results from robustness testing of the proposed RRLC method for determination of oseltamivir phosphate.	81
19	Determination of oseltamivir phosphate in pharmaceutical formulation by the proposed RRLC method and application of standard addition technique.	82
20	Statistical comparison between the proposed RRLC method and the official * method for determination of oseltamivir phosphate.	82
21	Results of assay validation obtained using the proposed HPLC method for determination of valaciclovir HCl in presence of its alkaline – and acid-degradata .	96
22	Accuracy of the proposed HPLC method for the analysis of pure samples of valaciclovir HCl.	97
23	Determination of valaciclovir HCl in laboratory prepared mixtures containing its acid- and alkaline –degradates by the proposed HPLC method.	97
24	System suitability parameters of the proposed HPLC method for determination of valaciclovir HCl.	98
25	Results from robustness testing of the proposed HPLC method method for determination of valaciclovir HCl.	98
26	Determination of valaciclovir HCl in pharmaceutical formulation by the proposed RRLC method and application of standard addition technique.	99
27	Statistical comparison between the proposed HPLC method and the manufacturer * method for determination of valaciclovir HCl.	99
28	Results of assay validation obtained using the proposed HPLC method for determination of oseltamivir phosphate in presence of its alkaline – degradata.	111
29	Accuracy of the proposed HPLC method for the analysis of pure samples of oseltamivir phosphate.	112
30	Determination of oseltamivir phosphate in laboratory prepared mixtures containing its alkaline –degradata by the proposed HPLC method.	112

31	System suitability parameters of the proposed HPLC method for determination of oseltamivir phosphate.	113
32	Results from robustness testing of the proposed HPLC method for determination of oseltamivir phosphate.	113
33	Determination of oseltamivir phosphate in pharmaceutical formulation by the proposed HPLC method and application of standard addition technique.	114
34	Statistical comparison between the proposed HPLC method and the official method for determination of oseltamivir phosphate.	114
35	Results of assay validation obtained using the proposed HPLC method for determination of zanamivir in presence of its acid -degrade.	126
36	Accuracy of the proposed HPLC method for the analysis of pure samples of zanamivir.	127
37	Determination of zanamivir in laboratory prepared mixtures containing its acid –degrade by the proposed HPLC method.	127
38	System suitability parameters of the proposed HPLC method for determination of zanamivir.	128
39	Results from robustness testing of the proposed HPLC method for determination of zanamivir.	128
40	Determination of zanamivir in pharmaceutical formulation by the proposed HPLC method and application of standard addition technique.	129
41	Statistical comparison between the proposed HPLC method and the manufacturer * method for determination of zanamivir.	129
42	Results of assay validation obtained using the proposed TLC method for determination of valaciclovir HCl in presence of its alkaline-degrade.	143
43	Accuracy of the proposed TLC method for the analysis of pure samples of valaciclovir HCl.	144
44	Determination of valaciclovir HCl in laboratory prepared mixtures containing its alkaline -degrade by the proposed TLC method.	144
45	Determination of valaciclovir HCl in pharmaceutical formulation by the proposed TLC method and application of standard addition technique.	145
46	Statistical comparison between the proposed TLC method and the Manufacturer * method for determination of valaciclovir HCl.	145